Table 4.
Demographic characteristics of the population under study.
| Training cohort | Validation cohort | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| dn2PD | CTR | P | dn2PD | CTR | P | advPD | P (advPD vs dn2PD) | P (advPD vs CTR) | |
| Age | 65.1 ± 9.4 | 64.5 ± 6.9 | 0.68 | 65 ± 11.4 | 71.7 ± 5.1 | 6 × 10–5 | 68.9 ± 7.3 | 0.05 | 0.16 |
| Sex (male/tot) | 40/72 | 36/59 | 0.53 | 83/156 | 8/20 | 0.26 | 15/22 | 0.19 | 0.07 |
| BMI | 27.7 ± 5 | 26.7 ± 3.8 | 0.25 | 27.1 ± 4.9 | 26.2 ± 3.2 | 0.35 | 25.9 ± 3.7 | 0.25 | 0.8 |
| UPDRS III | 19 ± 10.2 | 0.4 ± 0.9 | 7.4 × 10–24 | 23 ± 12.8 | / | / | 34.4 ± 15.8 | 0.003 | / |
| Hoehn and Yahr stage | 1.8 ± 0.6 | 0 | 1.6 × 10–35 | 2 ± 0.8 | / | / | 3.1 ± 0.6 | 6.7 × 10–8 | / |
| MMSE | 28.4 ± 1.3 | 28.7 ± 1.2 | 0.27 | 28 ± 1.9 | / | / | 23.3 ± 5.4 | 0.002 | / |
| Subjects taking Chol-lowering drugs/tot) | 7/72 | 3/59 | 0.32 | 32/156 | / | / | 5/22 | 0.39 | / |
| Diabetes (cases/tot) | 4/72 | 3/59 | 0.9 | 21/156 | 0/20 | / | 2/22 | 0.57 | / |
| Uric acid lowering medications | 8/72 | 3/59 | 0.21 | 12/156 | 2/20 | 0.72 | 2/22 | 0.82 | 0.92 |
Mean ± standard deviation and p-value (P) are reported.